Feature | EP Mapping and Imaging Systems | July 01, 2015

Medtronic Announces Acquisition of CardioInsight Technologies

CardioInsight's ECVUE non-invasive cardiac mapping system becomes part of Medtronic line

Medtronic, CardioInsight, acquisition, ECVUE, cardiac mapping system

July 1, 2015 - Medtronic has acquired CardioInsight Technologies Inc., a Cleveland-based medical device company that has developed a new approach to improve the mapping of electrical disorders of the heart. CardioInsight will become part of the Medtronic atrial fibrillation solutions business in the cardiac rhythm and heart failure division.

Medtronic completed its acquisition of CardioInsight on a debt-free basis in a transaction valued at approximately $93 million, net of CardioInsight's cash of $7 million, plus performance-based contingent consideration that may be paid post-closing. Consideration consisted of an initial cash payment of $75 million and retirement of a Medtronic loan outstanding to CardioInsight in the amount of $25 million. Additional terms of the deal were not disclosed.

The CardioInsight ECVUE system is designed to non-invasively generate images of the electrical activity of the heart by combining body surface electrical data with 3-D anatomical data. The system then reconstructs and displays 3-D maps and other useful measures of cardiac electrical activity. The ECVUE system has been used with more than 1,400 patients in Europe and the United States, and it also has been featured in more than 120 peer reviewed journals and presentations.

Medtronic will include revenue from the CardioInsight product line as part of the cardiac rhythm and heart failure division within the cardiac and vascular group. The transaction is expected to meet Medtronic's long-term financial metrics for acquisitions, and the annualized earnings impact of this acquisition is not expected to be material.

For more information: www.medtronic.com

Related Content

News | EP Lab

November 22, 2021 — BioSig Technologies Inc., a medical technology company commercializing an innovative biomedical ...

Home November 22, 2021
Home
Videos | EP Lab

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz ...

Home November 22, 2021
Home
Feature | EP Lab

November 18, 2021 — The U.S. Food and Drug Administration (FDA) is reminding providers about the risk of major ...

Home November 18, 2021
Home
News | EP Lab

November 16, 2021 — Acutus Medical Inc. (Acutus), an arrhythmia management company focused on improving the way cardiac ...

Home November 16, 2021
Home
News | EP Lab

November 15, 2021 — Vektor Medical Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Home November 15, 2021
Home
Feature | EP Lab | By Arnaud Rosier, M.D.

With 1.2 to 1.4 million new electrophysiology (EP) devices being prescribed to patients around the world each year ...

Home October 28, 2021
Home
News | EP Lab

October 28, 2021 — CathVision, a medical technology company developing electrophysiology (EP) solutions in EP recording ...

Home October 28, 2021
Home
News | EP Lab

October 6, 2021 – Biosense Webster announced the first cases using a radiofrequency balloon ablation catheter were ...

Home October 06, 2021
Home
News | EP Lab
October 1, 2021 — The European Society of Cardiology (ESC) guidelines on cardiac pacing and cardiac resynchronization ...
Home October 04, 2021
Home
Videos | EP Lab
Khaldoun Tarakji, M.D., MPH, associate section head, cardiac electrophysiology, Heart and Vascular Institute at ...
Home October 04, 2021
Home
Subscribe Now